Sildenafil
Product Images NDC 50090-4644

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 50090-4644). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500904644)

Packaging label for Sildenafil 25 mg tablets from A-S Medication Solutions. The label includes the product NDC 50090-4644-0 and states each tablet contains sildenafil citrate equivalent to 25 mg sildenafil. Storage instructions specify keeping the product at 68 to 77 degrees Fahrenheit. The package contains 10 tablets.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 1)

Chemical structure of Sildenafil, showing its molecular components including a piperazine ring, sulfonyl group, and other characteristic functional groups.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 2)

A line graph comparing systolic blood pressure changes (mmHg) over 24 hours after dosing. The x-axis shows time post dose in hours from Pre-Dose to 24 hours. Two lines represent the changes: one for Sildenafil 100 mg and one for Placebo, showing varying blood pressure responses over time.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 3)

A line graph showing the change in systolic blood pressure (SBP) in mmHg over time post dose (hours). It compares two groups: one receiving Doxazosin with Placebo and the other receiving Doxazosin with Sildenafil 25 mg, plotted over an 8-hour period.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 4)

Line graph depicting change in systolic blood pressure (SBP) over time (hours) post dose, comparing two treatments: Doxazosin plus Placebo and Doxazosin plus Sildenafil 50 mg. The x-axis shows time from 0 to 8 hours, and the y-axis shows change in SBP in mmHg, ranging from -50 to 40.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 5)

A line graph comparing the effect of Doxazosin combined with Sildenafil 100 mg versus Doxazosin combined with placebo over 8 hours. The y-axis represents mmHg, and the x-axis represents time after dosing in hours. Two lines illustrate changes over time for each treatment group.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 6)

A line graph showing plasma concentration (ng/ml) over time (hours) after administration of a commercial tablet of Sildenafil by A-S Medication Solutions. The graph plots drug concentration from 0 to 24 hours post-dose, illustrating a rapid increase to peak concentration followed by a gradual decline.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 7)

A bar chart titled 'Effect of sildenafil on Maintenance of Erection by Baseline Score' showing percentage of patients at endpoint on the vertical axis and baseline score on the horizontal axis. Multiple bars for each baseline score represent categories 0 to 5, illustrating distribution of patient outcomes across different baseline scores.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 8)

A bar chart titled 'Effect of Placebo on Maintenance of Erection by Baseline Score' showing the percentage of patients at endpoint across different baseline scores from 0 to 5. The bars are grouped by baseline score and categorized with a legend numbered 0 to 5. The vertical axis represents the percentage of patients at endpoint, ranging from 0 to 80%.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 9)

A bar chart showing the percentage of patients reporting improvement across four treatment groups: Placebo (24%), Sildenafil 25 mg (63%), Sildenafil 50 mg (74%), and Sildenafil 100 mg (82%). The x-axis represents treatment groups and the y-axis shows percentage improvement. The overall treatment p-value is less than 0.0001.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.